TNFRSF8 and anaplastic large cell lymphoma: While Brentuximab Vedotin showed a significant activity in relapsed/refractory ALCL, with response rate up to 86% and median PFS of 13.3 months, its use in non-ALCL CD30+ PTCL was associated with a limited benefit [5, 29].